pegvisomant
Sign in to saveAlso known as GH-N, Growth hormone, GH, Pituitary growth hormone, Somatotropin precursor, Growth hormone 1, B2036-PEG
Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin.
Wikidata facts
Show 1 more fact
- defined daily dose
- 10.0
via Wikidata · CC0
~2 min read
Article
8 sectionsContents
- Medical uses
- Side effects
- Discovery
- Structure
- Mechanism of action
- Research
- References
- External links
Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin.
== Medical uses == Pegvisomant is indicated for the treatment of adults with acromegaly.
Available in 16 languages
- Español
- Français
- Deutsch
- 日本語
- Português
- Italiano
- العربية
- Macedonian
- Odia
- Polski
- Serbian
- Serbian (Latin)
- Slovenian
- Tiếng Việt
- Ukrainian
via Wikidata sitelinks · CC0